★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
GSK plc
GSK · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
GSK plc is a global biopharma company focused on Specialty Medicines, Vaccines, and General Medicines. FY2025 growth shifted mix toward Specialty Medicines, especially HIV, respiratory/immunology and oncology, while Q1 2026 continued that pattern with Specialty Medicines sales up 14% CER, Vaccines up 4%, and General Medicines down 6%. The moat is mainly time-bounded IP and regulatory exclusivity, plus manufacturing scale, quality/compliance execution and clinical development capability. Respiratory inhalers add modest device-training switching friction, but payer formularies can override it. Key risks are patent cliffs, vaccine demand volatility, reimbursement pressure, and pipeline execution.
Primary segment
Specialty Medicines
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-07-01
Segments
Vaccines
Human vaccines
Revenue
28%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
Revenue
41.2%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
General Medicines
Respiratory inhaled therapies and established branded medicines
Revenue
30.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Vaccines
Human vaccines
FY2025 Vaccines turnover was GBP9.157bn, or 28.0% of Commercial Operations turnover. Q1 2026 Vaccines sales were GBP2.1bn, +4% CER, with Shingrix +20%, meningitis vaccines -3%, and Arexvy -18%. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Large, regulated vaccines manufacturing and biologics know-how remain difficult to replicate quickly, though 2025 growth shifted toward Shingrix and meningitis rather than RSV.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Peers and CDMOs expanding biologics/vaccine capacity
- Process standardization lowering manufacturing barriers
- Supply chain disruptions reducing reliability advantage
Leading indicators
- Vaccine doses delivered and OTIF performance
- Regulatory inspection outcomes (warning letters/critical findings)
- Major product recalls or supply interruptions
Counterarguments
- Large vaccine competitors can match capex and talent
- Contract manufacturing can partially substitute for in-house scale
Compliance Advantage
Legal
Compliance Advantage
Strength
Durability
Confidence
Evidence
High compliance/quality track record lowers supply disruption risk and supports tender/customer confidence.
Compliance Advantage moat: definition, examples, and stocks
Erosion risks
- Quality lapses leading to warning letters/consent decrees
- Tightening regulatory requirements increasing costs
- Serialization/counterfeit risks in some markets
Leading indicators
- FDA/EMA inspection results and remediation timelines
- Batch rejection/recall frequency
- Publicly disclosed manufacturing deviations
Counterarguments
- Compliance is a baseline requirement for all large pharma
- A single adverse inspection can quickly damage perceived advantage
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/exclusivities on key adult vaccines support differentiation, but protection is time-bounded and Arexvy is already facing weaker US demand after its post-launch surge.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and biosimilar/next-gen vaccine entry
- Competitors improving safety/efficacy profiles
- Government tender pricing reducing returns despite IP
Leading indicators
- Competitor trial readouts in overlapping indications
- Patent challenges or adverse litigation outcomes
- ACIP/EMA label and recommendation changes
Counterarguments
- Vaccine IP does not guarantee sustained share if rivals launch better products
- Tender-driven markets can commoditize even differentiated vaccines
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
FY2025 Specialty Medicines turnover was GBP13.474bn, or 41.2% of Commercial Operations turnover, led by HIV GBP7.687bn, RI&I GBP3.810bn and Oncology GBP1.977bn. Q1 2026 Specialty Medicines sales were GBP3.2bn, +14% CER. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Core earnings power is increasingly tied to patent-protected specialty assets, notably HIV, respiratory/immunology and oncology, that restrict generic competition during exclusivity windows.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Price controls and reimbursement tightening
- Clinical differentiation narrowing vs competitors
Leading indicators
- Patent litigation outcomes and generic filing activity
- Payer/formulary moves against branded regimens
- Share shifts in HIV and oncology classes
Counterarguments
- Even under patent, payers can steer volume to alternatives
- Pipeline execution is required to replace revenue at LOE
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Large R&D investment and clinical development capabilities support a sustained pipeline, but outcomes are uncertain and peers have similar scale.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- R&D productivity declines (failed trials, delays)
- Loss of key scientific talent
- Regulatory setbacks in priority programs
Leading indicators
- Phase III/registration readouts vs guidance
- Approvals per year and label breadth
- Pipeline mix shifting toward higher-value specialty categories
Counterarguments
- Scale does not guarantee drug discovery success
- Competitors can outspend in key modalities or indications
General Medicines
Respiratory inhaled therapies and established branded medicines
FY2025 General Medicines turnover was GBP10.036bn, or 30.7% of Commercial Operations turnover, with respiratory GBP7.068bn and Trelegy GBP2.986bn. Q1 2026 General Medicines sales were GBP2.3bn, -6% CER, with Trelegy GBP0.6bn stable. Sources: https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf and https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf.
Switching Costs General
Demand
Switching Costs General
Strength
Durability
Confidence
Evidence
Device-specific inhaler technique and patient training create friction in switching, but payers can still mandate changes.
Switching Costs General moat: definition, examples, and stocks
Erosion risks
- Payers forcing non-medical switches
- Generic and me-too inhalers reducing differentiation
- Digital training and standardization reducing technique barriers
Leading indicators
- Formulary exclusions/rebates impacting share
- Generic entry timing and substitution rates
- Adherence and persistence metrics for inhaled therapies
Counterarguments
- Switching costs are modest; clinicians can retrain quickly
- Insurers can override patient/provider preference via formularies
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Trelegy retains some patent protection and remains a key respiratory growth driver, but many older general medicines face generic competition.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic/biosimilar entry
- Device patent workarounds by competitors
- Pricing pressure via payer rebates
Leading indicators
- Patent challenges and settlements
- Competitor inhaler launches and generic approvals
- Net price trends (rebate/discount intensity)
Counterarguments
- Even with patents, payers can compress net pricing through rebates
- Competitors can launch therapeutically similar combinations
Evidence
Vaccines 9,157
Shows 2025 Vaccines turnover of GBP9.157bn, including Shingrix, meningitis, RSV, influenza and established vaccines.
In 2024, we had 104 regulatory inspections. We received zero warning letters from the US FDA.
Demonstrates execution capability under strict regulatory oversight.
Shingrix zoster vaccine recombinant, adjuvanted
The 2025 patent table lists Shingrix patent expiry as 2029 in the US and 2031 in the EU.
Dovato dolutegravir, lamivudine HIV/AIDS
The 2025 patent table lists Dovato patent expiries/ranges through 2028-2034 across territories.
Bepirovirsen, potential functional cure for chronic hepatitis B
Signals pipeline breadth and continued late-stage filing progress in specialty categories.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Peers and CDMOs expanding biologics/vaccine capacity
- Process standardization lowering manufacturing barriers
- Supply chain disruptions reducing reliability advantage
- Quality lapses leading to warning letters/consent decrees
- Tightening regulatory requirements increasing costs
- Serialization/counterfeit risks in some markets
Leading indicators
- Vaccine doses delivered and OTIF performance
- Regulatory inspection outcomes (warning letters/critical findings)
- Major product recalls or supply interruptions
- FDA/EMA inspection results and remediation timelines
- Batch rejection/recall frequency
- Publicly disclosed manufacturing deviations
Research GSK elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.